Trial Profile
Phase 1 Multiple Dose Trial to Assess the Safety, Tolerability and Efficacy of Four Different Dosing Regimens of Cross-Linked Polyelectrolyte (CLP) in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Talinexomer (Primary)
- Indications Heart failure
- Focus Pharmacodynamics
- Sponsors Sorbent Therapeutics
- 14 Mar 2014 New trial record